Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Parallel Study With an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men

NCT01816295 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01816295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01816295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Parallel Study With an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2013
Completion date
April 30, 2015
Enrollment
715 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

hypogonadism